

Substitute for form 1449-PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;">(Use as many sheets as necessary)</p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; background-color: #f2f2f2;">Complete if Known</th> </tr> <tr> <td style="width: 30%;">Application Number</td> <td>09/925,284-Conf. #2660</td> </tr> <tr> <td>Filing Date</td> <td>August 9, 2001</td> </tr> <tr> <td>First Named Inventor</td> <td>Daniel HAWIGER</td> </tr> <tr> <td>Art Unit</td> <td>1644</td> </tr> <tr> <td>Examiner Name</td> <td>R. B. Schwadron</td> </tr> <tr> <td>Attorney Docket Number</td> <td>RUJ-001CNCPRCE2</td> </tr> </table>		Complete if Known		Application Number	09/925,284-Conf. #2660	Filing Date	August 9, 2001	First Named Inventor	Daniel HAWIGER	Art Unit	1644	Examiner Name	R. B. Schwadron	Attorney Docket Number	RUJ-001CNCPRCE2
Complete if Known																	
Application Number	09/925,284-Conf. #2660																
Filing Date	August 9, 2001																
First Named Inventor	Daniel HAWIGER																
Art Unit	1644																
Examiner Name	R. B. Schwadron																
Attorney Docket Number	RUJ-001CNCPRCE2																
Sheet	2	of	3														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*
	C1	Badlee, Ali et al., "Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205," <i>Vaccine</i> , Vol. 25:4757-4766 (2007)	
	C2	Bonifaz, Laura et al., "Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class II Products and Peripheral CD8+T Cell Tolerance," <i>J. Exp. Med.</i> , Vol. 196(12):1627-1938 (2002)	
	C3	Chien, Nadine C. et al., "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 86:5532-5536 (1989)	
	C4	Steinman, Ralph M., "Dendritic cells and immune-based therapies," <i>Experimental Hematology</i> , Vol. 24:859-862 (1996)	
	C5	Tan, M.C. Agnes A. et al., "Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells," <i>Eur. J. Immunol.</i> , Vol. 27:2426-2435 (1997)	
	C6	Invitation to Pay Additional Fees for Application No. PCT/US2008/082745, dated February 12, 2009	
	C7	International Search Report and Written Opinion for Application No. PCT/US2008/082745, dated July 8, 2009	
	C8	International Search Report and Written Opinion for Application No. PCT/US04/02725, dated January 3, 2005	
	C9	International Search Report and Written Opinion for Application No. PCT/US02/36036	
	C10	International Search Report and Written Opinion for Application No. PCT/US01/15114	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO. Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known Application Number 09/925,284-Conf. #2660 Filing Date August 9, 2001 First Named inventor Daniel HAWIGER Art Unit 1644 Examiner Name R. B. Schwadron	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>					
Sheet	3	of	3	Attorney Docket Number RUJ-001CNCPRCE2	

[illegible]

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO. Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached